Edition:
India

Taro Pharmaceutical Industries Ltd (TARO.N)

TARO.N on New York Stock Exchange

106.29USD
12:38am IST
Change (% chg)

$0.63 (+0.60%)
Prev Close
$105.66
Open
$105.61
Day's High
$107.50
Day's Low
$105.61
Volume
30,902
Avg. Vol
34,113
52-wk High
$157.84
52-wk Low
$92.28

TARO.N

Chart for TARO.N

About

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical... (more)

Overall

Beta: 0.81
Market Cap(Mil.): $4,335.46
Shares Outstanding(Mil.): 41.03
Dividend: --
Yield (%): --

Financials

  TARO.N Industry Sector
P/E (TTM): 8.33 29.74 30.35
EPS (TTM): 12.69 -- --
ROI: 30.42 15.90 15.27
ROE: 30.53 17.00 16.60

BRIEF-Taro Pharmaceutical Industries names Uday Baldota CEO

* Taro Pharmaceutical Industries Ltd- Uday Baldota as chief executive officer

22 Nov 2016

BRIEF-Taro Pharmaceutical Industries qtrly loss per share $0.00

* Taro Pharmaceutical Industries Ltd - qtrly loss per share $0.00

09 Nov 2016

BRIEF-Taro appoints new chief financial officer

* Appointment of Mariano Balaguer as vice president, CFO and chief accounting officer, effective today Source text for Eikon: Further company coverage:

04 Oct 2016

U.S. Justice Department subpoenas Taro over generic drug pricing

WASHINGTON Taro Pharmaceutical Industries Ltd and two of its senior officers received grand jury subpoenas last week in connection with a federal antitrust investigation into generic drug pricing, the company disclosed.

12 Sep 2016

UPDATE 1-U.S. Justice Department subpoenas Taro over generic drug pricing

WASHINGTON, Sept 11 Taro Pharmaceutical Industries Ltd and two of its senior officers received grand jury subpoenas last week in connection with a federal antitrust investigation into generic drug pricing, the company disclosed.

12 Sep 2016

BRIEF-Taro posts qtrly earnings per share $2.59

* Quarterly earnings per share $2.59 Source text for Eikon: Further company coverage:

11 Aug 2016

BRIEF-Taro Pharma CEO Kal Sundaram to return to Sun Pharma headquarters by the end of 2016

* Taro ceo Kal Sundaram to return to Sun Pharma headquarters by the end of 2016

07 Jul 2016

BRIEF-Amarin appoints Michael Kalb chief financial officer

* Kalb joins Amarin from Taro Pharmaceutical Industries Ltd Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

30 Jun 2016

Earnings vs. Estimates